DrugPatentWatch Database Preview

Details for Patent: 8,497,277

« Back to Dashboard

Which drugs does patent 8,497,277 protect, and when does it expire?

Patent 8,497,277 protects IMBRUVICA and is included in two NDAs.

This patent has one hundred and seventeen patent family members in twenty-six countries.

Summary for Patent: 8,497,277

Title:	Inhibitors of Bruton's tyrosine kinase
Abstract:	Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s):	Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee:	Pharmacyclics, Inc. (Sunnyvale, CA)
Application Number:	13/312,606
Patent Claim Types: see list of patent claims	Use; Device; Delivery;

Drugs Protected by US Patent 8,497,277

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No						TREATMENT OF MARGINAL ZONE LYMPHOMA
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No						TREATMENT OF MANTLE CELL LYMPHOMA
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No						TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA
Pharmacyclics Inc	IMBRUVICA	ibrutinib	CAPSULE;ORAL	205552-002	Dec 20, 2017		RX	Yes	No						TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

Non-Orange Book US Patents Family Members for Patent 8,497,277

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
9,181,263	Inhibitors of bruton's tyrosine kinase
8,754,091	Inhibitors of bruton's tyrosine kinase
8,748,439	Inhibitors of Bruton's tyrosine kinase
8,236,812	Inhibitors of bruton's tyrosine kinase

International Patents Family Members for US Patent 8,497,277

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	531263
Australia	2006348662
Australia	2008232762
Australia	2010201052